Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Kinnate Biopharma Inc. KNTE NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$30.00
+1032.1%

Kinnate Biopharma Inc. (KNTE) is a Biotechnology company in the Healthcare sector, currently trading at $2.65. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is KNTE = $30 (+1032.1% upside).

Net income is $113M (loss), growing at -59.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $159M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 13.19 (strong liquidity). Debt-to-assets is 1.8%. Total assets: $174M.

Analyst outlook: 2 / 6 analysts rate KNTE as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$30.00
▲ 1032.08% Upside
Average Price Target
The 12-month price target for Kinnate Biopharma Inc. is $30.00.

KNTE SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KNTE

✓
VALUE Pass
100/100
KNTE trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $30, implying +1032.1% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
KNTE: +0%/yr revenue is, -59.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet KNTE: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 13.19 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
KNTE: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 2 / 6 analysts rate KNTE as buy (33%). Analyst consensus target is $30 (+1032.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.04-7.185
Volume2.12M
Avg Volume (30D)367.16K
Market Cap$124.99M
Beta (1Y)1.34
Share Statistics
EPS (TTM)-2.42
Shares Outstanding$46.58M
IPO Date2020-12-03
Employees84
CEONima Farzan
Financial Highlights & Ratios
Gross Profit$-799K
EBITDA$-118.21M
Net Income$-112.65M
Operating Income$-119.01M
Total Cash$154.03M
Total Debt$3.18M
Net Debt$-53.82M
Total Assets$173.61M
Price / Earnings (P/E)-1.1
Analyst Forecast
1Y Price Target$30.00
Target High$30.00
Target Low$30.00
Upside+1,032.1%
Rating ConsensusHold
Analysts Covering6
Buy 33% Hold 67% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS49705R1059

Price Chart

Track all markets on TradingView
KNTE
Kinnate Biopharma Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.04 52WK RANGE 7.19

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.54
-0.89%
 AMAM
AMAM
Ambrx Biopharma Inc.
$28.00
+0.07%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.75
+0.87%
 KROS
KROS
Keros Therapeutics, Inc.
$11.71
+1.39%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message